Comments on India’s draft biotech patent guidelines posted
Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX
Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Comments on India’s draft biotech patent guidelines posted

The India Patent Office has released public feedback to its draft guidelines for the examination of biotechnology patents

The guidelines were released on December 11 2013 with a public comment period until January 11. The Patent Office received comments from Indian biotechnology firms, patent law firms, and groups such as the Organisation of Pharmaceuticals Producers of India (OPPO), the Biotechnology Industry Organization (BIO) and even the Japan Intellectual Property Association.

The Spicy IP blog described the publication as a “welcome development”.

The introduction to the draft guidelines state that they are intended to address serious concerns concerning “novelty, obviousness, industrial applicability, extent of disclosure and clarity in claims” which often arise in biotechnology patents. The guidelines also note that there are issues unique to biotechnology, “such as those relating to moral and ethical concerns, environmental safety, issues relating to patenting of ESTs (expressed sequence tags) of partial gene sequences, cloning of farm animals, stem cells, [and] gene diagnostics”.

Representatives of rights holders have expressed concern that the guidelines take too strict a view on patentability. OPPI, the industry group for large international pharmaceutical companies, said in its submission that the guidelines used an overly broad definition of obviousness. It also said that some of the provisions lacked clarity, that some limitations such as the prohibition of patenting methods of treatment appear to be broader in the guidelines’ examples than in the guideline text.

Similarly, Anand & Anand, who represents a number of large international pharmaceutical companies, stressed in its comments that the draft outlines do not have the force of law and argue that some of the illustrations are inconsistent with Patent Office practice.

more from across site and ros bottom lb

More from across our site

Dana Northcott, INTA’s 2024 president and associate general counsel for Amazon's IP team, talks about her work for the association
Managing IP reveals highlights from the INTA Annual Meeting, including law firms’ diversity and ESG concerns and a new beginning for a Chinese firm
Firms with a broad geographic reach are more likely to win work, especially from global companies with high turnovers, according to survey data of nearly 29,000 corporate counsel
IP STARS, Managing IP’s accreditation title, reveals its latest rankings for trademark work today, including which firms are on the up
Highlights from Sunday included judicial insight from across the globe and a keynote address from Martin Luther King Jr’s daughter
Managing IP’s senior reporter Rani Mehta interviewed attendees at the INTA Annual Meeting in Atlanta about how they made the most out of their first day
A team of lawyers who joined Norton Rose Fulbright from Polsinelli say they were drawn to the firm's global platform
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Lawyers say a ruling concerning liability for trademark infringement could give company directors an easy way out and create litigation uncertainty
The LMG Life Sciences Awards announces the winners for the 5th annual awards
Gift this article